Buying Cannabis Sardinia

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buying Cannabis Sardinia

Check out our CBD shop online sativa hemp offerings. Legal cannabis sale CBD shop Sardinia online. Our CBD shop Sardinia sells high quality, natural and organic products online and in its Villaricca location; hemp inflorescence products, CBD oils Sardinia, hemp supplements, shop cannabis light Sardinia hemp foods, hemp cosmetics, make-up, textiles, veterinary products, vaporizers, hemp A Sardinia e-liquids for cigarettes. Discover hemp products against insomnia, hemp products to regain appetite, Sardinia hemp products against depression, many hemp products against stress and anxiety and other hemp products against migraine until you find benefits against degenerative diseases. Cannabis shop Sardinia and sale high quality and all-natural legal cannabis products, CBD shop Sardinia operates in full compliance with the law and for this reason Erba Farm has opened a store where people of all ages can feel free to buy body creams, face creams, hair and hygiene products etc. Our company sells legal cannabis Sardinia online such as hemp seeds Sardinia, hemp tea and herbal tea, CBD oil Sardinia. Our CBD shop Sardinia sells online products derived from the processing of legal cannabis Sardinia, a plant used for millennia throughout the world, until the advent of the prohibition era, which greatly curbed this industry. CBD shop Sardinia with the goal of bringing to the attention of an ever-widening public the many uses and benefits of such products. In recent years, we are witnessing a revaluation of the medicinal and food properties of cannabis, as well as its use as a raw material in industrial sectors such as: textiles, construction, paper, energy Under the banner of better eco-sustainability, a rehabilitation that, albeit with difficulty, is also involving Italy. Log in. Lost your password? Remember me. Devi avere almeno 18 anni per visualizzare la pagina. Service Notice: Please be informed that international shipments are suspended until January 1st. Quick view. Add to wishlist. This option is required. CBD oil for anxiety and sleep deficiency remedies. Shopping cart Close. Sign in Close. No account yet? Create an Account. Piu di 18 anni Meno di 18 anni. My account. Hi, welcome to Herb Farm how can we help you?

Is Weed Legal In Italy For Tourists?

Buying Cannabis Sardinia

Studio Legale Bulleri offers assistance and legal solutions in the field of civil law, with a particular focus on the areas of corporate and commercial law. The firm strives to pre-empt and resolve conflicts in a transactional manner, aiming to avoid litigation wherever possible. A key objective is safeguarding the business interests of companies and resolving any disputes that may arise between shareholders or between companies and third parties. Finally, it takes care of all aspects concerning the economic and financial restructuring of companies in crisis due to over-indebtedness, and debt collection procedures with banks and various corporate creditors. Studio Legale Bulleri also provides advisory and advocacy services in the cannabis and industrial hemp sector for the strategic business development of start-ups and companies in Italy and the EU. The regulatory landscape surrounding cannabis is intricate, varying significantly based on its intended use, ranging from pharmaceutical to cosmetic, food, technical, and industrial applications. To navigate these complexities with clarity, it is practical to categorise the discussion into three distinct sections:. Article 14, paragraph 1, letter b of this Act stipulates the inclusion of cannabis and its derivatives in Table II of narcotic substances subject to supervision, prohibiting cannabis in its various forms, including flowers and leaves, oil and resin. In Italy, cannabis is, as a rule, a narcotic substance, subject to exceptions based on its scope and intended use. Cultivation, extraction of active ingredients, distribution, import and export are in fact subject to authorisation by the Ministry of Health — Central Narcotics Office l'Ufficio Centrale Stupefacenti , UCS , which is the state agency for cannabis intended for scientific or research purposes. The Ministry of Health Decree dated 9 November adopted the Collaboration Agreement between the Ministry of Health and the Ministry of Defence for the launch of the Pilot Project for the national production of cannabis-based substances and preparations of plant origin. The purpose of this project was to develop national production in order to supplement the imports of cannabis that had hitherto been exported to Italy by the Office for Medicinal Cannabis of the Dutch Ministry of Health, Welfare and Sport Bedrocan, Bediol, Bedrobinol and Bedica. Recently, a public call for tenders was launched for the cultivation of cannabis for therapeutic use to be contracted to the SCFM. The selection and award process is still pending see 3. Physicians may prescribe magistral preparations to be prepared by a pharmacist upon presentation of a non-repeatable medical prescription using Dronabinol or cannabis-based plant active substance for medical use. Physicians must supplement the prescriptions with anonymous patient data on age, sex, dosage by weight of cannabis and treatment requirements according to the relevant form, which must then be transmitted to the competent region for statistical purposes. All physicians may prescribe cannabis regardless of their specialisation. Magistral preparations can be used in two different ways: orally or by inhalation. Despite the national provision for reimbursement, the practical application of this law varies significantly across different Italian regions. Each region is responsible for establishing its own technical modalities for the reimbursement process. This means if a product with specific characteristics could be classified as both a medicine and another type of product it will be treated as a medicine. In June , the Ministry of Health published guidelines for obtaining authorisations for the cultivation of cannabis intended for CBD extraction for medical use. This process requires a double authorisation:. In essence, a prior agreement is required between the farm which is authorised to grow and supply the product to the pharmaceutical company and the pharmaceutical company which is authorised to supply the hemp produced by the farm, as well as the extraction of API. To date, only two extraction licences have been issued. Finally, it should be mentioned that by Ministerial Decree dated 7 August , the Ministry of Health lifted the suspension of the so-called Speranza Decree, which included CBD-containing preparations for oral use in the table of narcotic drugs annexed to the Narcotics Act. This decree has been challenged and is currently suspended by the competent Administrative Court, with the next hearing set for September Hemp is defined as cannabis sativa L. The cultivation of hemp can be carried out by the farmer without the need for prior authorisation. The farmer is only obliged to keep the seed card for one year and the purchase invoice for the period required by tax regulations ten years. If police controls detect THC levels exceeding 0. However, it is critical to note that the farmer is shielded from criminal liability provided they have adhered to the stipulations of Article 3 of the same law. This includes maintaining proper documentation such as the card and seed purchase invoices, which serve as proof of compliance with regulatory requirements. Checks must be carried out by the Carabinieri Forestali according to the method of sampling and analysis foreseen in Annex I of Reg. EU no. This list is considered exhaustive and requires compliance with regulations specific to each application. Hemp-based foods in Italy are regulated by the Ministerial Decree of the Ministry of Health dated 4 November , which states:. The Ministerial Decree in question provides for the possibility of introducing additional foodstuffs containing hemp, but this would require presenting new scientific evidence to support such inclusion. For further details, please see the Trends and Development article. According to the tables attached thereto, and also by virtue of the BELFRIT agreement signed with Belgium and France, only supplements based on hemp seeds or hemp seed oil are permitted in Italy. To date, products based on parts other than seeds or extracts cannot therefore be considered food or food supplements at the regulatory level. For other issues, such as novel food and expected developments, see 3. This regulation is supplemented by the Cosmetic Ingredient Database CosIng List , which, while not legally binding, is widely regarded as a key reference point for industry professionals. In Italy, CBD and CBG in their isolated forms are recognised as permissible ingredients for use in cosmetic formulations provided they are produced synthetically or obtained from non-prohibited parts of the cannabis sativa L. This category can be considered the only product category in which CBD oils can be considered compliant with regulations. The field of floriculture is regulated by a multitude of EU-derived regulations, which outline the scope of application of the legislation with important terminological and definitional specifications, as well as indicating the authorisation system and the requirements for conducting floricultural activities. It is therefore clear that Article 2 2 g , having included cultivation for floricultural purposes among the mandatory legal uses of hemp, makes it lawful to also produce these plants and their parts for ornamental purposes. It can therefore be considered that in Italy the production and sale of ornamental hemp plants is lawful provided they are germinated from certified seeds. This guidance explicitly states that ornamental hemp, including its various plant parts like flowers, leaves, fronds, and cuttings, is lawful as long as it is intended for end-use in an ornamental capacity only. This use excludes any possibility of further floricultural activities. Since ornamental hemp is not intended for human consumption, concerns regarding its psychotropic effects are largely irrelevant. By way of analogy, one may cite the example of oleander, a plant known to be toxic, which is freely sold without any special precautions being taken. However, the regulation of flowers is complex and intrinsically linked to the issues dealt with in the appropriate section below. Fibres do not present any particular legal or interpretative problems as they are unquestionably lawful. The problems, on the other hand, concern the supply chain as there are critical production issues due to the scarcity of processing plants. The matter was referred to the United Sections of the Supreme Court of Cassation, which ruled, while also calling on the legislature to provide clarity on the matter, that:. In the absence of legislative clarification, the sale of CBD flowers has become a widespread but legally precarious practice across Italy. Enforcement varies significantly, with authorities handling cases discretionally, leading to a patchwork of legal interpretations and enforcement practices. This has resulted in numerous seizures and criminal proceedings, each treated differently depending on the region and specific circumstances. In essence, a paradoxical situation has arisen in which industrial hemp flowers and resins are not covered by the law at least for retail sale , but their sale does not involve criminal offences since they do not have an intoxicating effect in practice. CBD flowers are in any case mostly sold for ornamental purposes as end products of the floricultural supply chain with a THC content of less than 0. In some cases, the limit of 0. Thus, in many cases, if the CBD flower limit is below this threshold, many proceedings end in dismissal or acquittal. The issue may be resolved in the pending criminal trial against Luca Marola, founder of Easy Joint, a pioneer company in the sector. He is accused in Parma of drug dealing for possessing kg of hemp sativa with a THC content of less than 0. This situation exemplifies the major problem plaguing the Italian system: chronic legal uncertainty. The lack of clear regulations forces businesses to navigate this uncertainty, often basing their operations on risk management strategies that vary by region. CBD oils present the same problems as CBD flowers with regard to the narcotics legislation, which are resolved by assessing psychotropic efficacy however, this is more straightforward as they are rarely marketed with a THC content higher than 0. At the same time, they present greater problems in relation to the regulation of medicinal products for the reasons set out above. This stems from the lack of a clearly defined offence, violating the principle that criminal offences require a clear taxonomical definition. In any case, the fate of these products is intrinsically linked to the appeal pending before the Administrative Court and the developments discussed in the Trends and Development article. The recreational use of cannabis is prohibited in Italy by the Narcotics Act. Possessing cannabis for personal use is not criminally prosecuted but is subject to administrative sanctions. It should be noted that the Supreme Court recently affirmed the principle that the cultivation of cannabis for personal use with rudimentary means does not constitute criminally relevant conduct. This orientation of the Supreme Court is instrumental in shaping the pending bills referred to in 3. The regulatory bodies that oversee the system for the production of pharmaceutical-grade cannabis and cannabinoids are essentially the UCS in its capacity as the State Cannabis Board established under the Single Convention and AIFA. In Italy, the field of medical cannabis is supported by a diverse and active network of associations that advocate for patient rights, address issues related to cannabis availability, reimbursement by the SSN, and the education of medical personnel. In the hemp sector, the Ministry of Agriculture has set up the Hemp Sector Table, in which stakeholders in the sector at the regulatory, scientific and association levels participate, and which is working on the new hemp sector plan. Active nationally are the associations Federcanapa, Canapa Sativa Italia, and Resilienza Italia, which deal with the promotion and protection of the supply chain. For years, operators in the sector in Italy have found themselves operating in a grey area, particularly regarding flowers and extracts. The United Sections of the Court of Cassation had already highlighted the need for clarifying legislation in Despite various amendment proposals, the law has not been supplemented and there is still a situation of general uncertainty, with differences in interpretation and application by the competent authorities from case to case and from area to area. The long-standing challenge for operators in the sector has been to obtain legal and regulatory clarity for the production and sale of flowers and extracts. For this reason, the lobbying activities carried out both through dialogue with the competent authorities and by challenging decrees detrimental to the sector see the Trends and Development article are cornerstones for the development and regulation of the industry. The main challenge is to delineate a field of application in the category of nutraceuticals, phytotherapeutic products and food supplements, which represent that intermediate band between foodstuffs and pharmaceuticals. In essence, it is a matter of carving out a legal and regulated sector for the production and sale of health products that are not the exclusive domain of pharmaceutical companies, but also of the industry in the sector, which in recent years has demonstrated its ability to capitalise on research results applied to the realisation of industrial products. In the medical cannabis sector, the fundamental challenge is to implement and develop national production by opening it up to private companies with production know-how superior to that of the SCFM. This objective presupposes a series of synergetic and strategic actions throughout the supply chain, starting with the training of medical personnel. To increase national production, it is necessary for the regions to transmit annual data on medical cannabis prescriptions to the Ministry of Health. Therefore, it is necessary for doctors to be adequately trained and informed about the potential of medical cannabis, as medical prescriptions are an essential element of the supply chain. The risks in the hemp industry are more pronounced compared to the medical cannabis sector, which benefits from clearer legislation. There remain numerous interpretative and application-related grey areas, creating an uncertain framework for industry operators. This is especially true for those dealing with CBD flowers and CBD oil, where legal uncertainties compel operators to make decisions based on risk management. Essentially, operating in this sector involves entrepreneurs consciously accepting a level of risk. Understanding the local culture and legal landscape is crucial for developing and managing business operations effectively. Given the complexity of the regulations and legal interpretations involved, it is vital for operators to engage with professionals who specialise in this area. Legal risks vary significantly across different production segments. The marketing of products, whether business-to-business B2B or business-to-consumer B2C , such as CBD flowers and CBD oil, often encounters significant legal challenges, including frequent product seizures. Additionally, the extraction of cannabinoids presents its own set of issues, stemming from the overlapping jurisdictions of narcotics and industrial hemp legislation. A thorough understanding of the specific legislation applicable to each sector, whether industrial, cosmetics, or others, is essential. Such knowledge enables proper activity framing and the effective management and profiling of associated risks. Regrettably, the industrial hemp sector still faces widespread risks, both criminal and administrative, which stem not only from narcotics legislation but also from the sector-specific regulations governing various uses. In Italy, cannabis in its forms such as flowers, leaves, oils, and resins is classified as a narcotic, subjecting it to strict controls and sanctions under narcotics legislation, despite ongoing legal disputes and differing interpretations. Consequently, all Italian police forces are authorised to conduct checks on cannabis and its derivatives as part of their judicial police duties. EU No. Most of these proceedings are concluded with dismissal if laboratory analyses confirm that the THC content is below the level that can produce psychotropic effects. In addition to the controls and sanctions arising from the Narcotics Act, it is also necessary to check compliance with the sector regulations relating to the individual uses of the products food, cosmetics, pharmaceuticals, etc. Non-compliance can lead to penal or administrative sanctions, including fines, suspension of activities, or other regulatory measures. Given the ambiguity in product classification, especially with CBD flowers and CBD oils, the potential issues arising from regulatory controls are varied and heavily dependent on the type of enforcement and the authority conducting it. Given the complexity of the regulations in this field, it is imperative for operators in the sector of hemp and its derivatives to seek legal advice. The industrial hemp and cannabinoid sector in Italy, much like in many other EU countries, continues to navigate through significant legal grey areas and risks. The stance of Italian authorities towards the hemp plant broadly aligns with that of Spain and Portugal, where currently only hemp seeds and fibres are recognised as legal. At the same time, recent rulings by the Administrative Court discussed in more detail in the Trends and Development article have affirmed the same principles established by the French Conseil d'Etat and even earlier by the European Court of Justice on the lawfulness of using the entire hemp plant from certified varieties. In any case, it is possible to say that the evolution of the sector, with particular reference to the food and supplement sector, will depend on the decisions at European level that will be taken by the EFSA see 3. In general, in view of the differences in interpretation of certain product categories between the various member states, the EU has started a process of acquiring data from operators in the sector in order to define a single European regulation in order to avoid alterations to the common market. Within the general European framework, an extremely important role will also be played by developments in the UK and Switzerland, countries which, although not part of the EU, nevertheless play a very important role in both regulatory and commercial terms. While access to medical cannabis in Italy is not hampered by major legal hurdles, the system suffers from limitations rooted in political choices. The production of medical cannabis is tightly controlled by the Ministry of Defence through the SCFM, alongside a reliance on imports, which underscores a major limitation in the current Italian system. A call for tenders was issued in to allow private companies to grow medical cannabis for supply to the SCFM. Companies were selected but to date the procedure is suspended while waiting for the Administrative Authority to rule on the appeals of some participants. The ideal solution would involve a significant policy shift, allowing private enterprises, once they have obtained the necessary authorisations, to cultivate and directly distribute medical cannabis to pharmacies in a free market system. However, such changes are complex and challenging to implement, suggesting a lengthy and difficult road ahead. At the same time, there has been an opening for the importation of cannabis and API-based medicines from other EU member states, as the Ministry of Health has authorised the importation of such products to certain pharmaceutical companies or distributors. While this approach broadens access to medical cannabis and could serve as a model for replication, it inadvertently places domestic producers at a disadvantage. Italy considers cannabinoids and all parts of the plant with the exception of seeds and derivatives as novel foods by not recognising their traditional use prior to 15 May At present, the application for CBD isolates extracted from the plant has been submitted and the relative risk assessment is pending, which, except for suspensions due to the further request for clarifications, will end in October Pending issues related to the use of parts other than seeds in food, also with reference to the use of hemp as a medicinal plant, are dealt with in the Trends and Development article. For a long time, there have been periodic initiatives to regulate the recreational use of cannabis. This proposal outlines specific provisions for both individual and collective cultivation. In the first case, cultivation of up to four plants and consequent possession of the proceeds is permitted, while collective cultivation consists of the opening of so-called cannabis social clubs, private associations with a maximum of members each, in which it is possible to cultivate a maximum of four plants per member. In this case, the sale of the finished product to members would be capped at 30 grams per month. The process of collecting the required 50, signatures to move the bill forward is expected to be completed by spring Following this, the bill will be submitted to either the Chamber of Deputies or the Senate of the Republic, where it will be scheduled for discussion. Given the precedents and the quality of the majority in parliament, which is composed of parties ideologically opposed to any form of cannabis regulation, it seems predictable that this initiative will not be followed up. The function of this initiative, however, according to the organisers, is to keep the political and social debate on narcotics alive, to create an even wider network of activists in view of future initiatives, and to demonstrate how Italian society is ready for the regulation of cannabis. The cannabis and cannabinoid sector in Italy is currently mired in significant legal uncertainty, largely due to how authorities interpret the nexus between narcotics laws, medicinal regulations, and legislation concerning industrial and European hemp. Despite global trends indicating a growing acceptance and interest in cannabis and its derivatives, Italian regulatory bodies maintain a stringent adherence to the strict letter of narcotics laws. This approach starkly overlooks recent updates in EU and national regulations specifically addressing cannabis from certified varieties. This rigid interpretation stands at odds with the original intent of narcotics legislation, which aims to prevent the consumption of substances that are toxic and harmful to humans. This foundational principle seems hardly applicable to cannabis products that, in practical terms, lack psychotropic effects. Such restrictive views have not only fostered a repressive regulatory stance towards emerging cannabis products, particularly flowers and extracts but have also given rise to many court cases in both criminal and administrative courts. Under their current interpretation, only hemp seeds and fibres are considered permissible, creating a stark contrast with both EU directives and national laws that are more inclusive. This law explicitly exempts certified hemp varieties from narcotics legislation. It defies logic that a plant classified as an agricultural product further reinforced by EU regulations can morph into a narcotic based solely on the harvested part. This restrictive interpretation has ignited strong opposition from legal scholars and courts. They point to the lack of psychoactive effects in industrial hemp and the contradiction with EU law as insurmountable obstacles to this theory. However, the decree controversially noted that while the cultivation of hemp seeds and fibres was governed by the national law on industrial hemp, the production of flowers and leaves would be governed by the Narcotics Act. The associations of the sector Canapa Sativa Italia, Resilienza Italia onlus, Sardinia Cannabis and Federcanapa challenged the decree, claiming that it was contradictory and in contrast with EU and constitutional law. The applicants pointed out that the supranational legislation and, in particular, the EU legislation did not distinguish between the parts of the hemp sativa plant coming from certified varieties classified as a whole as an agricultural product. Consequently, the contested decree resulted in an infringement of EU law in that it imposed a de facto quantitative restriction on the common market that was not justified by scientifically relevant public health protection requirements. These rulings have been challenged by the competent Ministries before the Council of State. Although a hearing has not yet been set for discussion, one is expected later in If the Italian Council of State confirms the judgments of the TAR Lazio, it could indeed herald a transformative period for the hemp industry in Italy. Under this new legal framework, farmers would be permitted to cultivate the entire Cannabis sativa plant, with the only requirement being compliance with Good Agricultural Collecting Practice GACP. Farmers may also carry out all the initial processing operations of the cultivated hemp that are indispensable for production needs. These consist of washing, defoliation, sorting, grading, hulling, drying, cutting and selection, pulverisation of the dried herbs, and obtaining essential oils from fresh plants directly on the farm, if the latter activity needs to be done with freshly harvested plants and plant parts. Also included in the initial processing stage, which is indispensable for production needs, is any activity aimed at stabilising and preserving the product intended for the subsequent stages of the supply chain. Particularly noteworthy is the possibility of using hemp as a medicinal plant. Pharmacists and herbalists could potentially prepare non-prepackaged, loose, extemporaneous food preparations containing whole hemp plants, extracts, or mixtures thereof. This could lead to the possibility of using the hemp plant for human consumption as an officinal plant, thus introducing a subject that inevitably intersects with pending cases concerning food hemp: the relationship with novel foods legislation on one hand, and the limits of THC in foodstuffs as a contaminant on the other. The safety of the product must, in fact, be assessed on the finished product itself based on the applicable regulations in the sector, not prejudged by preemptively prohibiting the use of certain plant parts. As affirmed by judgments from the CJEU, the French Council of State, and the Italian Administrative Court, such blanket bans contravene EU law by undermining the common market organisation without grounding in proven scientific requirements, relying solely on a generic precautionary principle and public health protection rationale. However, current regulations specify THC limits only for seeds and their derivatives, leaving a regulatory gap for other plant parts and extracts. In this regard, the application proposed by the EIHA Project the consortium promoted by the EIHA for the recognition of full-spectrum hemp extracts as novel foods represents a potential breakthrough. This application, based on an innovative scientific study, could be a valid tool to demonstrate that, like many herbal preparations eg, alcoholic tinctures or extracts of various medicinal plants or food supplements, what matters is not the absolute threshold of the presence of the contaminant, but rather the daily intake dosage. Another extremely pertinent issue among the potential scenarios relates to the free movement of goods within the European common market. The aforementioned judgments have, in fact, reaffirmed that national laws restricting the use of whole plants or the sale of CBD products legally produced in a member state constitute a quantitative restriction on the common market, and are therefore unlawful unless grounded in proven scientific necessity. However, when scrutinised, the evidence put forth by member states that had adopted restrictive regulations proved only to rely on generic, unproven public health protection rationales and a broad precautionary principle. These measures, together with the political choice of some member states eg, the Czech Republic and Poland have led to a scenario in which CBD products are lawfully produced in certain countries while banned in others. This has precipitated a clear distortion of the common market and competitive landscape, as many member states cannot produce certain products or cultivate and utilise the whole plant, yet must contend with imports of those very same products from states where they are legally produced. This creates a risk of a two-speed Europe that must be averted. The aim is to reinforce the European common market and safeguard it from imports of goods from non-EU countries, which possess vast resources posing a formidable threat to the European market at the detriment of producers within the member states. It is therefore imperative that the sector operates by harmonising the legal sphere with scientific research in order to uphold a new conception of sustainability, yielding innovative products for consumers characterised by superior quality and an inextricable link to their territory of origin. It would be desirable for hemp to follow in the footsteps of wine by cultivating production specifications intrinsically tied to geographical provenance, developing genetics tailored to various latitudes, and establishing self-regulatory standards adeptly integrating and interpreting existing regulations. This would mirror the path forged by organic products in s Italy, where self-regulation initially compensated for regulatory deficiencies before being enshrined into law. In parallel, it is also prudent to explore further applications. The experience of some member states, such as Belgium and Luxembourg, demonstrates that hemp can also be included in inhalation products. In Italy, adding inhalation as a recognised use for hemp could align with consumer preferences and expand the market. However, this should not become the sole recognised use for hemp but rather a complementary option alongside existing applications. The inclusion of hemp as an inhalation product requires careful consideration of tax regulations. This oversight is essential not only to protect consumers but also to ensure that the state collects appropriate revenues from this new market segment. Moreover, tax regulations need to be fair and effective, reflecting the unique characteristics of the hemp sector, which is predominantly made up of small and medium-sized enterprises and features craftsmanship akin to that found in the wine or craft beer industries. One potential solution could be to envisage a flat-rate system for artisanal hemp products intended for inhalation and, as far as marketing is concerned, apply by analogy the provisions for liquid inhalation products. These proposals are still under discussion and evaluation within the supply chain committee established at the Ministry of Agriculture. Chambers and Partners website Toggle navigation. Last Updated May 30, Law and Practice Trends and Developments. Law and Practice. Expand All. Regulatory Framework. To navigate these complexities with clarity, it is practical to categorise the discussion into three distinct sections: medical cannabis; industrial hemp from certified varieties ; and recreational cannabis. This authorisation allows them to manufacture cannabis extracts containing cannabinoids for API production. Separate authorisation is needed for the supply of starting plant material hemp and the destruction of any narcotic substances THC. Hemp and Cannabinoids Hemp is defined as cannabis sativa L. This law incentivises: cultivation and processing; use and final consumption of semi-finished hemp products from priority local supply chains; development of integrated territorial supply chains that enhance the results of research and pursue local integration and real economic and environmental sustainability; production of foodstuffs, cosmetics, biodegradable raw materials and innovative semi-finished products for industries in various sectors; and implementation of bioengineering, land reclamation, educational and research activities. Foods Hemp-based foods in Italy are regulated by the Ministerial Decree of the Ministry of Health dated 4 November , which states: permitted hemp-based foods are only seeds and derivatives oil and flour ; and the THC limits allowed are 5 ppm for oil and supplements and 2 ppm for seeds and flour. Floriculture The field of floriculture is regulated by a multitude of EU-derived regulations, which outline the scope of application of the legislation with important terminological and definitional specifications, as well as indicating the authorisation system and the requirements for conducting floricultural activities. Fibres Fibres do not present any particular legal or interpretative problems as they are unquestionably lawful. The UCS issues authorisations for the cultivation and supply of hemp to pharmaceutical workshops. The UCS issues authorisations for cannabis cultivation for research purposes. The UCS determines annually the quantities of medical cannabis needed on the basis of data communicated by the regions. AIFA is the national public body that regulates medicines for human use in Italy. AIFA is the competent agency for the recognition of pharmaceutical workshop quality. The following should also be noted: To date, the SCFM is the only institute in Italy authorised to cultivate cannabis for medical use. The regions are responsible for the reimbursability of cannabis as a medicine to citizens, and on an annual basis must communicate to the Ministry of Health the data regarding the amount of cannabis prescribed in the relevant regional territory for medical use. Hemp For years, operators in the sector in Italy have found themselves operating in a grey area, particularly regarding flowers and extracts. Medical Cannabis In the medical cannabis sector, the fundamental challenge is to implement and develop national production by opening it up to private companies with production know-how superior to that of the SCFM. For penalties, see 1. Cross-Jurisdictional Matters. Legal and Regulatory Developments. Prior authorisation by the EFSA is therefore required for their production and marketing. The application for authorisation of full-spectrum extracts will also be submitted shortly. Trends and Developments. Introduction The cannabis and cannabinoid sector in Italy is currently mired in significant legal uncertainty, largely due to how authorities interpret the nexus between narcotics laws, medicinal regulations, and legislation concerning industrial and European hemp. Law and Practice Author. Trends and Developments Author. Select Topic s. Please select at least one chapter and one topic to use the compare functionality. Chambers and Partners make no representation or endorsement of the quality and services supplied by companies or firms that may be found on this website. In no event will Chambers and Partners be liable for any damages including, without limitation, indirect or consequential damages, or any damages whatsoever arising from use or loss of use, data, or profits, whether in action of contract, negligence or other tort action, arising out of or in connection with the use of the website.

Buying Cannabis Sardinia